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Hypoxic-ischemic (HI) brain injury is one of main causes of long-term neurologic disability, morbidity 
and death worldwide in adults and children. This public health concern is mainly characterized by a 
decrease in oxygen concentration and blood flow to the tissues, which lead to cell death by energy 
depletion and increases free radical generation and inflammation, caused by an inefficient supply of 
nutrients to the brain. Hypoxic-ischemic brain injury occurs in perinatal asphyxia (PA), an obstetric 
complication associated with an impaired gas exchange[1]. The incidence of PA is estimated at 1/1000
live births in developed countries. Currently, there are no effective pharmaceutical strategies to prevent 
the triggering of secondary injury cascades, including oxidative stress and metabolic dysfunction. 
Neuroactive steroids like selective estrogen receptor modulators, SERMs, exert several 
neuroprotective effects. These include a decrease in reactive oxygen species, mitochondrial survival
and maintenance of cell viability. In this context, these neurosteroids constitute promising molecules, 
which could modify brain response to injury, motivated us to investigate the role of Raloxifene, a
selective estrogen receptor modulator in astrocytic cells under a HI injury. To replicate the conditions 
that occur in the presence of deprivation or decrease in O2 and glucose levels several studies have 
proposed a model of O2 and glucose deprivation (OGD)[1]. For this study T98G cells were seeded 
onto 24-wells plates in DMEM culture medium containing 10% FBS at seeding density of 10,000 cells 
per well and incubated for 2–3 days until they reach confluence. Subsequently, medium was changed 
to glucose-free DMEM, and then incubated in 1% O2 in a hypoxia incubator (Hypoxia Incubator 
Chamber, STEMCELL) for 9 hours. This was followed by reperfusion by changing the media to high 
glucose DMEM supplemented with 10% FBS and transferring the cells to 37°C in 95% air/5% CO2 
in  normal conditions, the control group was maintained in normal conditions of O2 and glucose during 
the experiment. For drug treatments cell cultures were incubated in DMEM serum-free medium 
containing 1, 0.1 and 0.01 uM Raloxifene, as co-treatment of OGD and reperfusion. Determination of 
Mitochondrial Mass was evaluated using Nonyl acridine orange (NAO). NAO is a cell-permeate, 
cationic fluorescent dye sequestered by active mitochondria [2] . After 3 of treatments, cells were 
loaded in the dark with 5 μM NAO at 37°C for 20 min. Thereafter, cells were washed with PBS to 
eliminate all non-sequestered dye. Mitochondrial mass was further evaluated by Fluorescence 
Intensity. DIC and fluorescence images were obtained with NIKON - Eclipse Ti-E PFS microscope.
The analysis of cellular fluorescence was performed using Fiji [3]. The microphotographs were loaded,
and background signals were eliminated from the images. Subsequently, 50 cells were randomly 
selected using a numbered grid in each microphotograph. The mean fluorescence value of the 50 cells 
was determined in eight microphotographs for each treatment using the Measure algorithm of Fiji and 
selecting each cell manually via ROI's (Regions of Interest) Management.There were no variations in 
the conditions of the image processing. Each assay was performed with a minimum of six replicate 
wells for each condition and experiments were repeated three times. Qualitative results suggested that 
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OGD may induce a loss of mitochondrial mass (Figure 1) and Raloxifene reduced this effect. 
Quantitative studies using fluorescence intensity for NAO confirmed these observations (Figure 2). 
OGD significantly reduced mitochondrial mass (p= 0,0094) in comparison to Control group, and 0.1 
uM Raloxifene significantly increased NAO fluorescence in OGD cells (p < 0,0196). Our results 
suggest that Raloxifene could be considered as a promising neuroprotective agent for HI injury. 
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Figure 1. The panel shows representative microphotographs of NAO fluorescence in T98G cells 
exposed to 9h OGD 3h Reperfusion  
 
Figure 2. Raloxifene preserves mitochondrial mass. The bar graph shows the values of NAO Mean 
fluorescence, data are represented as Mean ± SEM of 3 independent experiments: Control (452,2 ± 
22,28), OGD (330,4 ± 23,45), OGD+0.1 uM Raloxifene (397,8±12,74), OGD+ 0.01 uM Raloxifene 
(374,6 ± 19,78). 
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